Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00094003 · ClinicalTrials.gov registry record · Phase 1
Study of NS-9 in Patients With Liver Metastases
A Phase 1 study, sponsored by NS Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00094003 is a Phase 1 study that has completed, run by NS Pharma. The registered enrollment target is 20 participants.
The verdict
NCT00094003, a Phase 1 study, has completed, sponsored by NS Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor. NS-9 is a drug developed to go to the liver to cause cell death specifically in tumor cells. This study is also set up to determine the best dose to use.
Interventions
- DRUG NS-9 [Poly I: Poly C]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2002-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00094003
The ClinicalTrials.gov registry entry for NCT00094003 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NS Pharma, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NS-9 [Poly I: Poly C] is the first listed.
NCT00094003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00094003 about?
NCT00094003 is a clinical study titled "Study of NS-9 in Patients With Liver Metastases". This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor. NS-9 is a drug developed to go to the liver to cause cell death specifically in tumor cells. This study is also set up t...
What is the current status of trial NCT00094003?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2002-09.
What interventions are being tested in trial NCT00094003?
The interventions under investigation include: NS-9 [Poly I: Poly C] (DRUG).
Who is sponsoring clinical trial NCT00094003?
This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.